Feb 13, 2020 - Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Feb 12, 2020 - Merck (NYSE:MRK) announces that a Phase 3 clinical trial, KEYNOTE-355, evaluating the combination of Keytruda (pembrolizumab) and chemo in patients with metastatic triple-negative breast cancer (T
Jan 31, 2020 - Provident Financial Services, Inc. (NYSE:PFS) Q4 2019 Results Earnings Conference Call January 31, 2020, 10:00 AM ET Company Participants Len Gleason - Investor Relations Officer Chris Martin - Chairm
Jan 31, 2020 - PFS earnings call for the period ending January 31, 2020.
Oct 25, 2019 - PFS earnings call for the period ending September 30, 2019.
Oct 25, 2019 - Provident Financial Services, Inc. (NYSE:PFS) Q2 2019 Earnings Conference Call October 25, 2019 10:00 AM ET Company Participants Len Gleeson - Investor Relations John Kuntz - Corporate Secretary Chris
Oct 25, 2019 - Provident Financial (PFS) delivered earnings and revenue surprises of 8.89% and 1.30%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Sep 30, 2019 - Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
Sep 30, 2019 - AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.
Sep 16, 2019 - Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.